The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient with Afatinib-Resistant Lung Cancer
Lei Gong,Jing Qin,Fajun Xie,Na Han,Hongyang Lu
DOI: https://doi.org/10.1016/j.jtho.2019.01.030
IF: 20.121
2019-01-01
Journal of Thoracic Oncology
Abstract:Tumor evolution is associated with drug resistance. Leptomeningeal metastasis (LM) is a fatal complication in patients with NSCLC. The blood-brain barrier protects the central nervous system from toxicity, but also prevents most therapeutic agents from accessing the brain parenchyma and leptomeningeal space.1Cheng H. Perez-Soler R. Leptomeningeal metastases in non–small-cell lung cancer.Lancet Oncol. 2018; 19: e43-e55Abstract Full Text Full Text PDF PubMed Scopus (147) Google Scholar Because of lower selection pressure, LM may evolve more slowly than extracranial lesions. A 58-year-old male patient with a 25-pack/year smoking history presented with cough in November 2016. The flow chart of diagnosis and treatment is shown in Figure 1. No abnormalities were found in brain enhanced magnetic resonance imaging. The patient was diagnosed with lung adenocarcinoma with pleura and right ilium metastases, cT2N2M1 (stage IV, EGFR exon 19 deletion). He developed primary pulmonary lesion transforming into squamous cell carcinoma and LM after drug resistance to afatinib. Plasma and cerebrospinal fluid (CSF) samples were collected for cell-free DNA extraction and subsequently examined by targeted next-generation sequencing (NGS) for 139 lung cancer–related genes (Supplemental Table 1) to a mean coverage depth of above 4500× (Illumina Hiseq, Illumina, San Diego, California). Tumor tissue was also tested by targeted NGS (Table1). The NGS results showed that EGFR mutation disappeared in peripheral blood and lung lesions, whereas EGFR exon 19 deletion mutation persisted in CSF (Figs. 2B–D). The addition of osimertinib on the basis of chemotherapy and bevacizumab resulted in rapid and long-term improvement in the symptoms of LM. The patient subsequently developed liver metastasis, which was confirmed by biopsy as squamous cell carcinoma. Interestingly, another EGFR mutation was found in the liver metastasis: EGFR exon 20 insertion(EGFR p. P772 delinsPHA) rather than the original exon 19 deletion (Figs. 2E and F).The level of serum squamous cell carcinoma antigen was gradually elevated during the course of the disease, whereas the level of serum carcinoembryonic antigen remained close to normal (Fig. 3).Table 1NGS Results of Different Times and Locations During the Disease Course of the PatientBefore TreatmentAfter Afatinib TreatmentAfter Liver MetastasisLungSerumLungCSFSerumLiverVariationVAFVariationVAFVariationVAFVariationVAFVariationVAFVariationVAFEGFRp.745_750del (c.2235_2249delGGAATTA AGAGAAGC)26.6%---p.745_750del (c.2235_2249delGGAATTA AGAGAAGC)53.4%p.P772delinsPHA (c.2314_2315 insCCCACG)1.1%p.P772delinsPHA (c.2314_2315 insCCCACG)1.5%EGFR--------Amplification3.9 timesAmplification10.7 timesPIK3CAp.H1047R34.8%--Amplification2.7 timesp.H1047R48.7%----RB1----Single copy loss-----TP53----p.S127Y87.7%Single copy loss-p.S127Y11.3%p.S127Y70.0%TP53--------Single copy lossKDR----p.D120G24.3%--p.D120G12.3%p.D120G21.5%KIT----Amplification10 times--Amplification2.2 timesAmplification3.4 timesLRP1B----p.D4156Y55%--p.D4156Y11.2%p.D4156Y50.5%SOX2----Amplification3.7 times----Amplification2.0 timesTET2----p.Q734X90.3%--p.Q734X26.7%p.Q734X82.3%CSF, cerebrospinal fluid; VAF, variant allele frequency; NGS, next-generation sequencing. Open table in a new tab Figure 2Visualization of EGFR mutations in the case using the Integrative Genomics Viewer (IGV). IGV display of (A) EGFR 19Del in a primary lung biopsy specimen, and of EGFR 19Del after progression of afatinib treatment in (B) plasma, (C) lung biopsy, (D) cerebrospinal fluid specimens, and of EGFR 20 Ins after liver progression in (E) plasma and (F) liver biopsy specimens.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3The variation curves of carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCCA).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3The variation curves of carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCCA).View Large Image Figure ViewerDownload Hi-res image Download (PPT) CSF, cerebrospinal fluid; VAF, variant allele frequency; NGS, next-generation sequencing. In this case, the transformation of adenocarcinoma to squamous cell carcinoma in primary pulmonary lesion was accompanied by the loss of EGFR mutation. Nevertheless, EGFR 19Del mutation persisted in CSF. Thus, the LM symptoms were quickly alleviated by osimertinib, which has remarkable efficacy in EGFR-mutated NSCLC patients with LM.2Tan C.S. Cho B.C. Soo R.A. Treatment options for EGFR mutant NSCLC with CNS involvement — can patients BLOOM with the use of next generation EGFR TKIs?.Lung Cancer. 2017; 108: 29-37Abstract Full Text Full Text PDF PubMed Scopus (36) Google Scholar More interestingly, after subsequent treatment, the patient developed a new EGFR exon 20 insertion mutation in liver metastases which was confirmed to be squamous cell carcinoma. There are three possible mechanisms to explain the tumor evolution in this patient. First, tumor cells acquire a different phenotype under the pressure of the irreversible pan-EGFR family inhibitor afatinib. The transformation results from molecular changes associated with afatinib treatment. EGFR exon 20 and PIK3CA mutations reportedly may be associated with squamous cell carcinoma.3Li S. Li L. Zhu Y. et al.Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.Br J Cancer. 2014; 110: 2812-2820Crossref PubMed Scopus (164) Google Scholar Second, the original tumor may be a mixed-type lung cancer such as an adenosquamous carcinoma, with two different types of EGFR mutations. Third, a second primary cancer appears. In conclusion, this case suggests that the evolution of extracranial lesions is different from LM in tumor morphology and gene inheritance. The combination of osimertinib, bevacizumab and chemotherapy effectively controlled LM and extracranial lesions. This study was supported by the Zhejiang province Medical Science and Technology Project (2018KY313). The authors thank the patient and his family. Download .doc (.05 MB) Help with doc files Supplemental Table 1